Know Cancer

forgot password

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma"

Phase 1
18 Years
Not Enrolling
B Cell Non-Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin

Thank you

Trial Information

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma"

Inclusion Criteria:

- Histologically confirmed diagnosis of any subtype of CD20+ B cell NHL. Subjects must
have disease that progressed after standard therapy or for which there is no
effective standard therapy (including high-dose therapy and autologous stem cell
transplantation). NOTE: If the subject has had a prior autologous stem cell
transplant, it must have occurred at least three months prior to screening and the
subject must be fully recovered from any acute toxicities.

- Prior treatment with Rituximab is allowed, provided it was completed at least six
months before study enrollment.

- Male or female ≥ 18 years of age.

- Measurable or evaluable disease.

- Predicted life expectancy of at least 12 weeks.

- ECOG Performance Status of 0 or 1.

- No chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer,
radiotherapy, or surgical procedures (except for minor surgical procedures) within
four weeks before beginning treatment with SB-485232 (6 weeks for nitrosoureas and
mitomycin C). Subjects must have recovered from toxicities (incurred as a result of
previous therapy) sufficiently to be entered into a Phase I study.

- A signed and dated written informed consent form is obtained from the subject.

- The subject is able to understand and comply with protocol requirements, timetables,
instructions and protocol-stated restrictions.

The subject is likely to maintain good venous blood access for PK and PD sampling
throughout the study.

- A female is eligible to enter and participate in the study if she is of:

a. non-childbearing potential (i.e., physiologically incapable of becoming pregnant)
including any female who:

- has had a hysterectomy,

- has had a bilateral oophorectomy (ovariectomy),

- has had a bilateral tubal ligation,

- is post-menopausal (demonstrate total cessation of menses for greater than 1year), If
amenorrheic for less than one year, post-menopausal status will be confirmed by serum
follicle stimulating hormone (FSH) and oestradiol concentrations at screening. or, b.
childbearing potential, has a negative serum pregnancy test at the Screen Visit, and
agrees to one of the following GSK acceptable contraceptive methods:

- any intrauterine device (IUD) with a documented failure rate of less than

1% per year.

- vasectomized partner who is sterile prior to the female subject's entry and is the
sole sexual partner for that female.

- oral contraceptive (either combined or progesterone only).

- because of the unacceptable failure rate of barrier (chemical and/or physical)
methods, the barrier method of contraception must only be used in combination with
other acceptable methods described above.

- Adequate organ function,

Exclusion Criteria:

- Women who are pregnant or are breast-feeding.

- Significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or
autoimmune conditions that in the opinion of the investigator and/or GSK medical
monitor, places the subject at an unacceptable risk as participant in this trial.

- The subject has diabetes mellitus with poor glycemic control.

- The subject has a history of human immunodeficiency virus (HIV) or other
immunodeficiency disease.

- The subject has positive Hepatitis B surface antigen.

- Corrected QT interval (QTc) > 480msec.

- The subject has a history of a severe infusion related reaction or tumor lysis
syndrome following treatment with Rituximab (Section 10.2.2).

- The subject has a circulating malignant cell count > 25,000/mm3 in peripheral blood.

- The subject has known anaphylaxis or IgE-mediated hypersensitivity to murine

- The subject has an acute infection or severe or uncontrolled infections requiring
systemic antibiotic therapy.

- Any serious medical or psychiatric disorder that would interfere with subject safety
or informed consent.

- Known leptomeningeal disease or evidence of prior or current metastatic brain
disease. Routine screening with central nervous system (CNS) imaging studies (CT or
MRI) is required only if clinically indicated.

- Receiving concurrent chemotherapy, immunotherapy, radiotherapy, or investigational

- Oral corticosteroids within 14 days of study entry.

- History of alcohol abuse within six months of screening or alcohol consumption in the
past six months exceeding seven drinks/week for women and 14 drinks/week for men
(where 1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor).

- History of ventricular arrhythmias requiring drug or device therapy.

- Any unresolved or unstable serious toxicity from prior administration of another
investigational drug.

- Any investigational drug within 30 days or five half-lives (whichever is longer)
preceding the first dose of SB-485232.

- Donation of blood in excess of 500 mL within a 56-day period prior to dosing.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

safety/tolerability of combination treatment for 4 weeks safety/tolerability of SB-485232 for additional 8 weeks

Outcome Time Frame:

12 weeks

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

July 2007

Completion Date:

March 2010

Related Keywords:

  • B Cell Non-Hodgkin's Lymphoma
  • Lymphoma, Non-Hodgkin
  • Rituximab,
  • oncology
  • IL-18,
  • combination study,
  • cytokine,
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell



GSK Investigational Site Indianapolis, Indiana  46260
GSK Investigational Site Park Ridge, Illinois  60068